Clinical Trial Update: Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1% [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 study is evaluating EVO101 0.1% topical cream for mild to moderate hidradenitis suppurativa and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• EVO101 (EVO101)

Snippet

Sponsor: Virginia Clinical Research, Inc. | Conditions: Hidradenitis Suppurativa (HS) | EARLY_Phase 1 | Status: RECRUITING